News + Filings Transactions Holdings
All
13F
13D/G
Other
|
|
BAKER BROS. ADVISORS LP
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 10/10/2023 |
4
| BAKER BROS. ADVISORS LP (10% Owner) has filed a Form 4 on Neoleukin Therapeutics, Inc.|
Txns:
| Exercised (in-or-at-the-money) 57,049 options to buy
@ $0
Exercised (in-or-at-the-money) 535,601 options to buy
@ $0 |
|
| 10/05/2023 |
4
| BAKER BROS. ADVISORS LP (Director) has filed a Form 4 on MADRIGAL PHARMACEUTICALS, INC.|
Txns:
| Bought 125,447 warrants
@ $0.0001, valued at
$12.5
Bought 1,522,651 warrants
@ $0.0001, valued at
$152.3 |
|
| 10/03/2023 |
4
| BAKER BROS. ADVISORS LP (Director) has filed a Form 4 on IGM Biosciences, Inc.|
Txns:
| Granted 554 shares
@ $0 |
|
| 10/03/2023 |
4
| BAKER BROS. ADVISORS LP (10% Owner) has filed a Form 4 on INCYTE CORP|
Txns:
| Granted 510 shares
@ $0 |
|
| 08/17/2023 |
4
| BAKER BROS. ADVISORS LP (10% Owner) has filed a Form 4 on Neoleukin Therapeutics, Inc.|
Txns:
| Bought 143,519 shares
@ $0.6308, valued at
$90.5k
Bought 1,740,581 shares
@ $0.6308, valued at
$1.1M
Bought 358 shares
@ $0.665, valued at
$238.1
Bought 4,342 shares
@ $0.665, valued at
$2.9k
Bought 17,124 shares
@ $0.6805, valued at
$11.7k
Bought 207,676 shares
@ $0.6805, valued at
$141.3k
Bought 366 shares
@ $0.6828, valued at
$249.9
Bought 4,434 shares
@ $0.6828, valued at
$3k
Bought 7,676 shares
@ $0.6924, valued at
$5.3k
Bought 93,091 shares
@ $0.6924, valued at
$64.5k
Bought 5,041 shares
@ $0.6928, valued at
$3.5k
|
|
| 07/05/2023 |
4
| BAKER BROS. ADVISORS LP (10% Owner) has filed a Form 4 on Kodiak Sciences Inc.|
Txns:
| Granted 40,000 options to buy
@ $6.9, valued at
$276k
|
|
| 07/05/2023 |
4
| BAKER BROS. ADVISORS LP (Director) has filed a Form 4 on IGM Biosciences, Inc.|
Txns:
| Granted 554 shares
@ $0 |
|
| 07/05/2023 |
4
| BAKER BROS. ADVISORS LP (10% Owner) has filed a Form 4 on INCYTE CORP|
Txns:
| Granted 512 shares
@ $0 |
|
| 06/28/2023 |
4
| BAKER BROS. ADVISORS LP (Director) has filed a Form 4 on IGM Biosciences, Inc.|
Txns:
| Bought 413,175 options to buy
@ $8, valued at
$3.3M
Bought 5,211,825 options to buy
@ $8, valued at
$41.7M
|
|
| 06/16/2023 |
4
| BAKER BROS. ADVISORS LP (10% Owner) has filed a Form 4 on INCYTE CORP|
Txns:
| Granted 2,505 shares
@ $0
Granted 11,294 options to buy
@ $61.44, valued at
$693.9k
Granted 11,294 options to buy
@ $61.44, valued at
$693.9k
|
|
| 06/12/2023 |
4
| BAKER BROS. ADVISORS LP (Director) has filed a Form 4 on Neoleukin Therapeutics, Inc.|
Txns:
| Granted 25,000 options to buy
@ $0.79, valued at
$19.8k
|
|
| 06/08/2023 |
4
| BAKER BROS. ADVISORS LP (Director) has filed a Form 4 on Kiniksa Pharmaceuticals, Ltd.|
Txns:
| Granted 8,746 shares
@ $0
Granted 52,472 options to buy
@ $15.19, valued at
$797k
Granted 52,472 options to buy
@ $15.19, valued at
$797k
|
|
| 06/05/2023 |
4
| BAKER BROS. ADVISORS LP (10% Owner) has filed a Form 4 on ACADIA PHARMACEUTICALS INC|
Txns:
| Granted 13,304 shares
@ $0
Granted 22,090 options to buy
@ $23.9, valued at
$528k
|
|
| 06/02/2023 |
4
| BAKER BROS. ADVISORS LP (10% Owner) has filed a Form 4 on Seagen Inc.|
Txns:
| Granted 2,044 shares
@ $0
Granted 2,044 shares
@ $0 |
|
| 05/24/2023 |
4
| BAKER BROS. ADVISORS LP (10% Owner) has filed a Form 4 on ACADIA PHARMACEUTICALS INC|
Txns:
| Bought 7,645 shares
@ $24.4604, valued at
$187k
Bought 82,148 shares
@ $24.4604, valued at
$2M
Bought 3,781 shares
@ $24.8, valued at
$93.8k
Bought 40,632 shares
@ $24.8, valued at
$1M
Bought 10,858 shares
@ $25.3302, valued at
$275k
Bought 116,672 shares
@ $25.3302, valued at
$3M
Bought 6,941 shares
@ $25.54, valued at
$177.3k
Bought 74,582 shares
@ $25.54, valued at
$1.9M
Bought 20,304 shares
@ $25.2723, valued at
$513.1k
Bought 218,171 shares
@ $25.2723, valued at
$5.5M
Bought 2,688 shares
@ $25.5138, valued at
$68.6k
|
|
| 05/24/2023 |
4
| BAKER BROS. ADVISORS LP (10% Owner) has filed a Form 4 on Prelude Therapeutics Inc|
Txns:
| Granted 121,178 options to buy
@ $5.75, valued at
$696.8k
Granted 1,327,044 options to buy
@ $5.75, valued at
$7.6M
Granted 970,220 options to buy
@ $0.0001, valued at
$97
Granted 10,625,036 options to buy
@ $0.0001, valued at
$1.1k
|
|
| 04/06/2023 |
4
| BAKER BROS. ADVISORS LP (10% Owner) has filed a Form 4 on IGM Biosciences, Inc.|
Txns:
| Granted 15,500 options to buy
@ $12.86, valued at
$199.3k
|
|
| 04/04/2023 |
4
| BAKER BROS. ADVISORS LP (10% Owner) has filed a Form 4 on INCYTE CORP|
Txns:
| Granted 429 shares
@ $0
Granted 429 shares
@ $0 |
|
| 04/04/2023 |
4
| BAKER BROS. ADVISORS LP (10% Owner) has filed a Form 4 on IGM Biosciences, Inc.|
Txns:
| Granted 554 shares
@ $0 |
|
| 03/15/2023 |
4
| BAKER BROS. ADVISORS LP (10% Owner) has filed a Form 4 on INCYTE CORP|
Txns:
| Exercised 20,000 options to buy
@ $22.74, valued at
$454.8k
Exercised 20,000 options to buy
@ $22.74, valued at
$454.8k
|
|
| 01/17/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 01/04/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 10/04/2022 |
4
| BAKER BROS. ADVISORS LP (10% Owner) has filed a Form 4 on INCYTE CORP|
Txns:
| Granted 457 shares
@ $0
Granted 457 shares
@ $0 |
|
| 07/05/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 07/01/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/30/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/24/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/22/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/17/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/13/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/13/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/09/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/06/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/06/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
|
|
|